Modern diagnostics of nonalcoholic fatty liver disease: noninvasive research methods
Abstract
Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as the most common cause of chronic liver disease worldwide. NAFLD represents a wide spectrum of conditions, ranging from simple benign steatosis to nonalcoholic steatohepatitis, which sometimes progresses to cirrhosis and hepatocellular carcinoma. The pivotal issue in the management of patients with NAFLD is the diagnosis of steatohepatitis and fibrosis at an early stage. In this review we present recent data on nonalcoholic fatty liver disease evaluation. Although liver biopsy is regarded as the gold standard for assessment of hepatic steatosis and steatohepatitis, its use has several limitations, including the potential risk of sampling errors, intra- and interobserver variability, invasiveness and the stress it causes to patients, the high cost and the potential for complications. In this review a simple and reliable non-invasive alternative with indicated sensitivity and specificity is described. Non-invasive markers should aim ; in primary care settings, to identify the risk of developing NAFLD among individuals with increased metabolic risk; in secondary and tertiary care settings, to identify those with a worse prognosis, e.g. severe steatohepatitis; monitor disease progression; predict response to therapeutic interventions. Achieving these objectives could reduce the need for liver biopsy. Thus, according to the natural history of NAFLD, all patients with a low risk of developing advanced disease, eventually diagnosed by one of above non-invasive parameters, could be referred to primary care, whereas subjects at high risk of developing advanced disease should be sent to specialists for the evaluation of the degree of fibrosis and the choice of specific management. According to the Clinical Practice Guidelines for the management of NAFLD, ultrasound is the preferred first-line diagnostic procedure for imaging of NAFLD, as it provides additional diagnostic information. Whenever imaging tools are not available or feasible (e.g. large epidemiological studies), serum biomarkers and scores are an acceptable alternative for the diagnosis of steatosis. The combination of biomarkers/scores and transient elastography might confer additional diagnostic accuracy. At the same time, the identification of advanced fibrosis or cirrhosis by serum biomarkers/scores and/or elastography is less accurate and needs to be confirmed by liver biopsy, according to the clinical context. Аlthough there are a range of controversial issues regarding the use of non-invasive methods for the assessment of NAFLD, these methods are being actively developed, researched and introduced into clinical practice as an equivalent and substitute for liver biopsy.References
Angulo, P., Hui, J.M., Marchesini, G., Bugianesi, E., George, J., Farrell, G.C., Enders, F., Saksena, S., Burt, A.D., Bida, J.P., Lindor, K., Sanderson, S.O., Lenzi, M., Adams, L.A., Kench, J., Therneau, T.M., Day, C.P., 2007. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45, 846–854. >> doi.org/10.1002/hep.21496
Armutcu, F., Akyol, S., Ucar, F., Erdogan, S., Akyol, O., 2013. Markers in nonalcoholic steatohepatitis. Adv. Clin. Chem. 61, 67–125. >> doi.org/10.1016/b978-0-12-407680-8.00004-x
Ballestri, S., Lonardo, A., Romagnoli, D., Carulli, L., Losi, L., Day, C.P., Loria, P., 2012. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int. 32(8), 1242–1252. >> doi.org/10.1111/j.1478-3231.2012.02804.x
Balmer, M.L., Joneli, J., Schoepfer, A., Stickel, F., Thormann, W., Dufour, J.F., 2010. Significance of serum adiponectin levels in patients with chronic liver disease. Clin. Sci. (Lond). 119, 431–436. >> doi.org/10.1042/cs20100008
Baratta, M., 2002. Leptin – from a signal of adiposity to a hormonal mediator in peripheral tissues. Med. Sci. Monit. 8, 282–292. >> doi.org/10.1055/s-2006-957677
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., Tiribelli, C., 2006. The fatty liver index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2, 26–33. >> doi.org/10.1186/1471-230x-6-33
Bodnar, P.M., Myhalchyshyn, G.P., Dynnik, O.B., Kobylyak, N.M., 2012. Ocinka diagnostichnoi efectivnosti elastographii hvyli zsuvu u khvorich na cukrovii diabet II typu z nealkoholnym steatohepatozom [Evaluation of diagnostic efficiency of shear wave elastography imaging in patients with type II diabetes with nonalcoholic steatohepatosis]. Endokrinologia 17(3), 38–48 (in Ukrainian).
Botros, M., Sikaris, K.A., 2013. The de Ritis ratio: the test of time. The Clinical Biochemist Reviews 34(3), 117–130.
Boyraz, M., Cekmez, F., Karaoglu, A., Cinaz, P., Durak, M., Bideci, A., 2013. Serum adiponectin, leptin, resistin and RBP4 levels in obese and metabolic syndrome children with nonalcoholic fatty liver disease. Biomark. Med. 7, 737–745. >> doi.org/10.2217/bmm.13.13
Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., Charlton, M., Sanyal, A.J., 2012. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55(6), 2005–2023. >> doi.org/10.1002/hep.25762
Dynnik, O.B., Linskaya, A.V., Kobylyak, N.N., 2012. Cdvigovovolnovaya elastographia s elastometria parenchsmy pecheni [Shear wave elastography imaging of liver parenchyma]. Promeneva Dіagnostika, Promeneva Terapіya 1–2, 73–82 (in Russian).
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, 2016. J. Hepatol. 64, 1388–1402. >> doi.org/10.1016/j.jhep.2015.11.004
Festi, D., Schiumerini, R., Marzi, L., Di Biase, A.R., Mandolesi, D., Montrone, L., Scaioli, E., Bonato, G., Marchesini-Reggiani, G., Colecchia, A., 2013. The diagnosis of non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 37(4), 392–400. >> doi.org/10.1111/apt.12186
Finelli, C., Tarantino, G., 2013. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World. J. Gastroenterol. 19(6), 802–812. >> doi.org/10.3748/wjg.v19.i6.802
Genc, H., Dogru, T., Kara, M., Tapan, S., Ercin, C.N., Acikel, C., Karslioglu, Y., Bagci, S., 2013. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann. Hepatol. 12, 548–555.
Idilman, I.S., Keskin, O., Celik, A., Savas, B., Halil Elhan, A., Idilman, R., Karcaaltincaba, M., 2016. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease. Acta. Radiol. 57(3), 271–278. >> doi.org/10.1177/0284185115580488
Joka, D., Wahl, K., Moeller, S., Schlue, J., Vaske, B., Bahr, M.J., Manns, M.P., Schulze-Osthoff, K., Bantel, H., 2012. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatol. 55, 455–464. >> doi.org/10.1002/hep.24734
Kim, Y.C., Cho, Y.K., Lee, W.Y., Kim, H.J., Park, J.H., Park, D.I., Sohn, C.I., Jeon, W.K., Kim, B.I, Park, S.E., Rhee, E.J., Park, C.Y., Oh, K.W., Park, S.W., Kim, S.W., Ryu, S.H., 2011. Serum adipocyte-specific fatty acidbinding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects. J. Nutr. Biochem. 22, 289–292. >> doi.org/10.1016/j.jnutbio.2010.02.007
Kobylyak, N.M., Bodnar, P.M., Myhalchyshyn, G.P., Dynnik, O.B., 2012. Diagnostichna efectivnist hepatorenalnogo indeksu u khvorich na cukrovii diabet II typu z nealkoholnym steatohepatozom [Diagnostic efficiency of hepatorenal index in patients with type II diabetes with nonalcoholic steatohepatosis]. Ukrainskii Medichnii Chasopys 92, 125–128 (in Ukrainian).
Kobylyak, N.M., Dynnik, O.B., Kiriyenko, D.V., 2015. Suchasnі pіdhody to dіagnostiki ta skrinіngu metabolіchnih porushen u khvoryh іz nealkogolnoyu zhirovoyu hvoroboyu pechіnki [Current approaches to diagnosis and screening of metabolic disorders in patients with nonalcoholic fatty liver disease]. Mizhnarodnii Endokrinologichnii Zhurnal 69 (in Ukrainian).
Kotronen, A., Peltonen, M., Hakkarainen, A., Sevastianova, K., Bergholm, R., Johansson, L.M., Lundbom, N., Rissanen, A., Ridderstråle, M., Groop, L., Orho-Melander, M., Yki-Järvinen, H., 2009. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterol. 137(3), 865–872. >> doi.org/10.1053/j.gastro.2009.06.005
Kumar, M., Rastogi, A., Singh, T., Behari, C., Gupta, E., Garg, H., Kumar, R., Bhatia, V., Sarin, S.K., 2013. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: Does etiology affect performance? J. Gastroenterol. Hepatol. 28, 1194–1201. >> doi.org/10.1111/jgh.12134
Lebensztejn, D.M., Wierzbicka, A., Socha, P., Pronicki, M., Skiba, E., Werpachowska, I., Kaczmarski, M., 2011. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with nonalcoholic fatty liver disease. Acta Biochim. Pol. 58, 563–566.
Lee, J.H., Kim, D., Kim, H.J., Lee, C.H., Yang, J.I., Kim, W., Kim, Y.J., Yoon, J.H., Cho, S.H., Sung, M.W., Lee, H.S., 2010. Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. Dig. Liver Dis. 42(7), 503–508. >> doi.org/10.1016/j.dld.2009.08.002
Leite, N.C., Salles, G.F., Cardoso, C.R., Villela-Nogueira, C.A., 2013. Serum biomarkers in type II diabetic patients with non-alcoholic steatohepatitis and advanced fibrosis. Hepatol. Res. 43, 508–515. >> doi.org/10.1111/j.1872-034x.2012.01106.x
Machado, M.V., Cortez-Pinto, H., 2013. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J. Hepatol. 58, 1007–1019. >> doi.org/10.1016/j.jhep.2012.11.021
Machado, M.V., Coutinho, J., Carepa, F., Costa, A., Proença, H., Cortez-Pinto, H., 2012. How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 24, 1166–1172. >> doi.org/10.1097/meg.0b013e32835609b0
Masaki, K., Takaki, S., Hyogo, H., Kobayashi, T., Fukuhara, T., Naeshiro, N., Honda, Y., Nakahara, T., Ohno, A., Miyaki, D., 2013. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol. Res. 43, 1182–1189. >> doi.org/10.1111/hepr.12094
McPherson, S., Stewart, S.F., Henderson, E., Burt, A.D., Day, C.P., 2010. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 59, 1265–1269. >> doi.org/10.1136/gut.2010.216077
Neuman, M.G., Cohen, L.B., Nanau, R.M., 2014. Biomarkers in nonalcoholic fatty liver disease. Can. J. Gastroenterol. Hepatol. 28(11), 607–618. >> doi.org/10.1155/2014/757929
Ozcelik, F., Yuksel, C., Arslan, E., Genc, S., Omer, B., Serdar, M.A., 2013. Relationship between visceral adipose tissue and adiponectin, inflammatorymarkers and thyroid hormones in obese males with hepatosteatosis and insulin resistance. Arch. Med. Res. 44, 273–280. >> doi.org/10.1016/j.arcmed.2013.04.001
Petta, S., Vanni, E., Bugianesi, E., Di Marco, V., Cammà, C., Cabibi, D., Mezzabotta, L., Craxì, A., 2015. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 35, 1566–1573. >> doi.org/10.1111/liv.12584
Pirvulescu, I., Gheorghe, L., Csiki, I., Becheanu, G., Dumbravă, M., Fica, S., Martin, S., Sarbu, A., Gheorghe, C., Diculescu, M., Copăescu, C., 2012. Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery. Chirurgia (Bucur). 107, 772–779.
Polyzos, S.A., Toulis, K.A., Goulis, D.G., Zavos, C., Kountouras, J., 2011. Serum total adiponectin in nonalcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism 60, 313–326. >> doi.org/10.1016/j.metabol.2010.09.003
Poynard, T., Lassailly, G., Diaz, E., 2012. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: Meta analysis of individual patient data. PLoS One 7(3), 303–305. >> doi.org/10.1371/journal.pone.0030325
Purnomo, H.D., Mundhofir, F.E., Kasno, Sudijanto, E., Darmono, D., Djokomoeljanto, R., Faradz, S.M., 2015. Combination of aspartate aminotranferase and tumor necrosis factor-α as non invasive diagnostic tools for non alcoholic steatohepatitis (NASH). Acta Med. Indones. 47(1), 16–23.
Regev, A., Berho, M., Jeffers, L.J., Milikowski, C., Molina, E.G., Pyrsopoulos, N.T., Feng, Z.Z., Reddy, K.R., Schiff, E.R., 2002. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol. 97, 2614–2618. >> doi.org/10.1111/j.1572-0241.2002.06038.x
Rinella, M.E., Loomba, R., Caldwell, S.H., Kowdley, K., Charlton, M., Tetri, B., Harrison, S.A., 2014. Controversies in the diagnosis and management of NAFLD and НАSH. Gastroenterol. Hepatol. (N.Y.) 10(4), 219–227.
Sandrin, L., Fourquet, B., Hasquenoph, J.M., Yon, S., Fournier, C., Mal, F., Christidis, C., Ziol, M., Poulet, B., Kazemi, F., Beaugrand, M., Palau, R., 2003. Transient elastography: A new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med. Biol. 29(12), 1705–1713. >> doi.org/10.1016/j.ultrasmedbio.2003.07.001
Sasso, M., Miette, V., Sandrin, L., Beaugrand, M., 2012. The controlled attenuation parameter (CAP): A novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin. Res. Hepatol. Gastroenterol. 36, 13–20. >> doi.org/10.1016/j.clinre.2011.08.001
Shen, F., Zheng, R.D., Mi, Y.Q., Wang, X.Y., Pan, Q., Chen, G.Y., Cao, H.X., Chen, M.L., Xu, L., Chen, J.N., Cao, Y., Zhang, R.N., Xu, L.M., Fan, J.G., 2014. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J. Gastroenterol. 20(16), 4702–4711. >> doi.org/10.3748/wjg.v20.i16.4702
Strobel, D., Takahashi, H., Yoneda, M., Suda, T., Zeuzem, S., Herrmann, E., 2012. Acoustic radiation force impulse-imaging for non-invasive assessment of liver fibrosis: A pooled meta-analysis. J. Viral. Hepat. 19(2), 212–219. >> doi.org/10.1111/j.1365-2893.2011.01537.x
Sumida, Y., Yoneda, M., Hyogo, H., 2012. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 12, 2–9. >> doi.org/10.1186/1471-230x-12-2
Tamimi, T.I., Elgouhari, H.M., Alkhouri, N., Yerian, L.M., Berk, M.P., Lopez, R., Schauer, P.R., Zein, N.N., Feldstein, A.E., 2011. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J. Hepatol. 54, 1224–1229. >> doi.org/10.1016/j.jhep.2010.08.023
Tarantino, G., Conca, P., Pasanisi, F., Ariello, M., Mastrolia, M., Arena, A., Tarantino, M., Scopacasa, F., Vecchione, R., 2009. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur. J. Gastroenterol. Hepatol. 21(5), 504–511. >> doi.org/10.1097/meg.0b013e3283229b40
Vernon, G., Baranova, A., Younossi, Z.M., 2011. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholicsteatohepatitis in adults. Aliment. Pharmacol. Ther. 34, 274–285. >> doi.org/10.1111/j.1365-2036.2011.04724.x
Wieckowska, A., Zein, N.N., Yerian, L.M., Lopez, A.R., McCullough, A.J., Feldstein, A.E., 2006. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatol. 44(1), 27–33. >> doi.org/10.1002/hep.21223
Wong, V.W., Vergniol, J., Wong, G.L., Foucher, J., Chan, H.L., Le Bail, B., Choi, P.C., Kowo, M., Chan, A.W., Merrouche, W., Sung, J.J., de Lédinghen, V., 2010. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatol. 51(2), 454–462. >> doi.org/10.1002/hep.23312
Yilmaz, Y., Yonal, O., Kurt, R., Bayrak, M., Aktas, B., Ozdogan, O., 2011. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepatitis Monthly 11(2), 103–107.
Zelber-Sagi, S., Ratziu, V., Zvibel, I., Goldiner, I., Blendis, L., Morali, G., Halpern, Z., Oren, R., 2012. The association between adipocytokines and biomarkers for nonalcoholic fatty liver diseaseinduced liver injury: A study in the general population. Eur. J. Gastroenterol. Hepatol. 24(3), 262–269. >> doi.org/10.1097/meg.0b013e32834f15dd
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons «Attribution» 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
